{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:20:13Z","timestamp":1788574813098,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Science and Technology","award":["MOST-111-2314-B-A49-036-MY3"],"award-info":[{"award-number":["MOST-111-2314-B-A49-036-MY3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-025-00843-2","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:16:43Z","timestamp":1767971803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SLC25A11-mediated reprogramming of mitochondrial redox state and lipid peroxidation confers NRF2-dependent ferroptosis resistance in biliary tract cancer"],"prefix":"10.1186","volume":"31","author":[{"given":"Yu-Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Hsi","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yi","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheorl-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ru","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsien","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"5","key":"843_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et\u00a0al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):14.","journal-title":"Ann Hepatol"},{"key":"843_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102170","author":"L Goyal","year":"2021","unstructured":"Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102170.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"843_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, et\u00a0al. Cholangiocarcinoma\u2014novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023;20(7):470\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"843_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100737","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022. https:\/\/doi.org\/10.1016\/j.aohep.2022.100737.","journal-title":"Ann Hepatol"},{"issue":"1","key":"843_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et\u00a0al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):17.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"843_CR6","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","volume":"288","author":"MD Pizzagalli","year":"2021","unstructured":"Pizzagalli MD, Bensimon A, Superti-Furga G. A guide to plasma membrane solute carrier proteins. FEBS J. 2021;288(9):2784\u2013835.","journal-title":"FEBS J"},{"issue":"10","key":"843_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25102417","volume":"25","author":"L Rochette","year":"2020","unstructured":"Rochette L, Meloux A, Zeller M, Malka G, Cottin Y, Vergely C. Mitochondrial SLC25 carriers: novel targets for cancer therapy. Molecules. 2020;25(10):15.","journal-title":"Molecules"},{"issue":"1","key":"843_CR8","first-page":"34","volume":"26","author":"A Ahmed","year":"2025","unstructured":"Ahmed A, Iaconisi GN, Di Molfetta D, Coppola V, Caponio A, Singh A, et\u00a0al. The role of mitochondrial solute carriers SLC25 in cancer metabolic reprogramming: current insights and future perspectives. Int J Mol Sci. 2025;26(1):34.","journal-title":"Int J Mol Sci"},{"issue":"SUPPL 1","key":"843_CR9","first-page":"S167","volume":"52","author":"K Zuna","year":"2023","unstructured":"Zuna K, Tyshchuk T, Beikbaghban T, Pohl EE. Uncovering the hidden role of 2-oxoglutarate\/malate carrier in uncoupling: implications for metabolic disorders and cancer. Eur Biophys J Biophys Lett. 2023;52(SUPPL 1):S167-S.","journal-title":"Eur Biophys J Biophys Lett"},{"issue":"1","key":"843_CR10","volume":"10","author":"GQ Pan","year":"2020","unstructured":"Pan GQ, Wang RB, Jia SN, Li YQ, Jiao Y, Liu N. SLC25A11 serves as a novel prognostic biomarker in liver cancer. Sci Rep. 2020;10(1):10.","journal-title":"Sci Rep"},{"issue":"1","key":"843_CR11","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11010061","volume":"11","author":"DA Linseman","year":"2023","unstructured":"Linseman DA, Winter AN, Wilkins HM. The 2-oxoglutarate carrier is S-nitrosylated in the spinal cord of G93A mutant hSOD1 mice resulting in disruption of mitochondrial glutathione transport. Biomedicines. 2023;11(1):10.","journal-title":"Biomedicines"},{"issue":"4","key":"843_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"XJ Jiang","year":"2021","unstructured":"Jiang XJ, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"843_CR13","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1111\/febs.16059","volume":"289","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang DL. Signaling pathways and defense mechanisms of ferroptosis. FEBS J. 2022;289(22):7038\u201350.","journal-title":"FEBS J"},{"issue":"5","key":"843_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang DL. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"843_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.redox.2021.102021","volume":"45","author":"S Jang","year":"2021","unstructured":"Jang S, Chapa-Dubocq XR, Tyurina YY, St Croix CM, Kapralov AA, Tyurin VA, et\u00a0al. Elucidating the contribution of mitochondrial glutathione to ferroptosis in cardiomyocytes. Redox Biol. 2021;45:11.","journal-title":"Redox Biol"},{"issue":"36","key":"843_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1073\/pnas.2117396119","volume":"119","author":"N Ta","year":"2022","unstructured":"Ta N, Qu C, Wu H, Zhang D, Sun TT, Li YJ, et\u00a0al. Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci U S A. 2022;119(36):12.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"843_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molmet.2023.101717","volume":"72","author":"MJ Heo","year":"2023","unstructured":"Heo MJ, Suh JH, Lee SH, Poulsen KL, An YA, Moorthy B, et\u00a0al. Aryl hydrocarbon receptor maintains hepatic mitochondrial homeostasis in mice. Mol Metab. 2023;72:11.","journal-title":"Mol Metab"},{"issue":"18","key":"843_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1126\/sciadv.abn2879","volume":"8","author":"YX Yuan","year":"2022","unstructured":"Yuan YX, Zhu CJ, Wang YL, Sun J, Feng JL, Ma ZW, et\u00a0al. \u03b1-Ketoglutaric acid ameliorates hyperglycemia in diabetes by inhibiting hepatic gluconeogenesis via serpina1e signaling. Sci Adv. 2022;8(18):17.","journal-title":"Sci Adv"},{"issue":"7826","key":"843_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-020-2732-8","volume":"585","author":"YL Zou","year":"2020","unstructured":"Zou YL, Henry WS, Ricq EL, Graham ET, Phadnis VV, Maretich P, et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature. 2020;585(7826):603.","journal-title":"Nature"},{"key":"843_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.redox.2019.101328","volume":"28","author":"G Miotto","year":"2020","unstructured":"Miotto G, Rossetto M, Di Paolo ML, Orian L, Venerando R, Roveri A, et\u00a0al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:10.","journal-title":"Redox Biol"},{"key":"843_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29905-1","author":"P Koppula","year":"2022","unstructured":"Koppula P, Lei G, Zhang YL, Yan YL, Mao C, Kondiparthi L, et\u00a0al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-29905-1.","journal-title":"Nat Commun"},{"issue":"17","key":"843_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2320934121","volume":"121","author":"L Gu","year":"2024","unstructured":"Gu L, Du Y, Chen J, Hasan MN, Clayton YD, Matye DJ, et al. Cullin 3 RING E3 ligase inactivation causes NRF2-dependent NADH reductive stress, hepatic lipodystrophy, and systemic insulin resistance. Proc Natl Acad Sci U S A. 2024;121(17):e2320934121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"843_CR23","doi-asserted-by":"publisher","first-page":"24218","DOI":"10.1038\/srep24218","volume":"6","author":"H Lan","year":"2016","unstructured":"Lan H, Tang Z, Jin H, Sun Y. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci Rep. 2016;6:24218.","journal-title":"Sci Rep"},{"key":"843_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102603","volume":"60","author":"AR Bourgonje","year":"2023","unstructured":"Bourgonje AR, Kloska D, Grochot-Przeczek A, Feelisch M, Cuadrado A, van Goor H. Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1\u03b1 and NRF2 as therapeutic targets. Redox Biol. 2023;60:13.","journal-title":"Redox Biol"},{"key":"843_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.freeradbiomed.2022.11.039","volume":"194","author":"J Zheng","year":"2023","unstructured":"Zheng J, Kim SJ, Saeidi S, Kim SH, Fang XZ, Lee YH, et al. Overactivated NRF2 induces pseudohypoxia in hepatocellular carcinoma by stabilizing HIF-1\u03b1. Free Radic Biol Med. 2023;194:347\u201356.","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"843_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11091810","volume":"11","author":"CD Bondi","year":"2022","unstructured":"Bondi CD, Rush BM, Hartman HL, Wang JX, Al-Bataineh MM, Hughey RP, et al. Suppression of NRF2 activity by HIF-1\u03b1 promotes fibrosis after ischemic acute kidney injury. Antioxidants. 2022;11(9):19.","journal-title":"Antioxidants"},{"key":"843_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","volume":"152","author":"F Ursini","year":"2020","unstructured":"Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic Biol Med. 2020;152:175\u201385.","journal-title":"Free Radic Biol Med"},{"key":"843_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119911","volume":"241","author":"YJ He","year":"2020","unstructured":"He YJ, Liu XY, Xing L, Wan X, Chang X, Jiang HL. Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:11.","journal-title":"Biomaterials"},{"issue":"2","key":"843_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","volume":"30","author":"G Lei","year":"2020","unstructured":"Lei G, Zhang YL, Koppula P, Liu XG, Zhang J, Lin SH, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146\u201362.","journal-title":"Cell Res"},{"key":"843_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biopha.2020.110108","volume":"127","author":"YT Sun","year":"2020","unstructured":"Sun YT, Chen P, Zhai BT, Zhang MM, Xiang Y, Fang JH, et\u00a0al. The emerging role of ferroptosis in inflammation. Biomed Pharmacother. 2020;127:10.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"843_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, et\u00a0al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):13.","journal-title":"Cell Death Dis"},{"issue":"5","key":"843_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","volume":"25","author":"H Sato","year":"2020","unstructured":"Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol. 2020;25(5):801\u20139.","journal-title":"Int J Clin Oncol"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-025-00843-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:49:00Z","timestamp":1774615740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-025-00843-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1186\/s11658-025-00843-2","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"After deliberation by the Ethics Committee of National Yang Ming Chiao Tung University, the design and plan of this research fully considered the principles of safety and fairness. The research content fully considered the requirements of patient rights and ethics, in accordance with the Declaration of Helsinki. There is no conflict of interest in the research content and results. The study received approval from the National Yang Ming Chiao Tung University Ethics Committee on 9 July 2024, under the ethical number NYCU113121AW. The animal experiments were performed in accordance with the Basel Declaration and were approved by the Academia Sinica Institutional Animal Care and Utilization Committee (IACUC, #23-07-2023). The ethics committee follows the guidelines of the International Council for Laboratory Animal Science (ICLAS) to ensure the ethical compliance of the experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflicts of interest were declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}